Synopses & Reviews
Among malignant tumors, adenocarcinomas of the esophagogastric junction show the highest increase in incidence over the past three decades in Western industrialized countries. Accordingly, much effort is being devoted to basic and translational research in order to combat this frequently deadly disease. This special volume, with contributions from experts in the field, covers all aspects of adenocarcinomas of the esophagogastric junction. Etiology, pathogenesis, classification, and clinical staging are discussed, and there is special emphasis on state of the art treatment techniques. The latter range from endoscopic mucosal resections or limited surgical resections for early cancers to multimodality treatment options for locally advanced tumors. Emerging quality issues in surgical management are also addressed. Detailed attention is paid to other important recent developments, including molecular response prediction in multimodality treatment and early metabolic response evaluation by PET and PET-CT during neoadjuvant treatment. The diagnosis of micrometastases and its potential impact on therapeutic strategies are explored, and the use of sentinel node technology is assessed. This volume will be of interest to all clinicians concerned with the diagnosis and management of this malignancy.
Review
From the reviews: "Adenocarcinoma of the Esophagogastric Junction provides today's most comprehensive and tailored description of the pathogenesis, diagnosis, staging, and therapy of malignancy of a single region within the upper digestive tract. ... The chapters are succinct and well written, and the topics follow a logical progression of thought. ... one reads through, a sense of 'order' is appreciated and this ultimately frames the barriers that exist in the care of these patients. I left this text with many new perspectives and a sense of 'purpose.'" (Blair A. Jobe, Journal of Gastrointestinal Cancer, Vol. 43, 2012)
Synopsis
Among malignant tumors, adenocarcinomas of the esophagogastric junction show the highest increase in incidence over the past three decades in Western industrialized countries. This special volume, with contributions from experts in the field, covers all aspects of the disease. Etiology, pathogenesis, classification, and clinical staging are discussed, and there is special emphasis on state of the art treatment techniques. The latter range from endoscopic mucosal resections or limited surgical resections for early cancers to multimodality treatment options for locally advanced tumors. Emerging quality issues in surgical management are addressed. Detailed attention is also paid to other important recent developments, including molecular response prediction, early metabolic response evaluation by PET and PET-CT, the diagnosis of micrometastases, and the use of sentinel node technology. This volume will be of interest to all clinicians concerned with the diagnosis and management of this malignancy.
Synopsis
This special volume, with contributions from experts in the field, covers all aspects of adenocarcinomas of the esophagogastric junction. Etiology, pathogenesis, classification, and clinical staging are discussed, and there is special emphasis on state of the art treatment techniques. The latter range from endoscopic mucosal resections or limited surgical resections for early cancers to multimodality treatment options for locally advanced tumors. Emerging quality issues in surgical management are also addressed.
Table of Contents
Epidemiology of adenocarcinoma of the esophagogastric junction (EJ).- Clinical classification systems.- Histopathologic classification.- The pathogenesis of Barrett's metaplasia and the progression to esophageal adenocarcinoma.- Differences in the molecular biology of adenocarcinoma of the EJ.- Clinical staging.- Endoscopic mucosal resection for staging and therapy.- Surgical strategies.- Current status of sentinal lymph node biopsy in adenocarcinoma of the EJ.- Current diagnosis and future impact of micrometastases for therapeutic strategies.- Quality indicators in the surgical management of adenocarcinoma of the EJ.- Perioperative and complication management.- Multimodality therapy.- Metabolic response evaluation by PET during neoadjuvant treatment.- Molecular response prediction in multimodality treatment.